Trial
NCT02677948
Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Phase IWITHDRAWNSAFETYConfidence: MEDIUM
Sponsor
University of Michigan Rogel Cancer Center
Collaborators
—
Condition
Chronic Lymphocytic Leukemia
Intervention
Pacritinib
Why stopped
FDA has placed all trials involving Pacritinib on Full Clinical Hold
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-09-06